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Background: The link between long-term ICS therapy and respiratory infection in COPD patients is controversial.
We investigated the effect of long-term use of inhaled corticosteroid on Toll like receptor 2 (TLR2) expression in
induced sputum from COPD patients.
Methods: 51 patients were divided into two groups according to their treatment history: long-term ICS treatment
group (patients who have used ICS (equivalent to Fluticasone Propionate (FP) ≥ 500 ug/day for more than 1 year)
(n = 21) and ICS naive group (who have never routinely used ICS before, n = 29). In their induced sputum, we
tested TLR2 extracellular and intracellular expression on macrophages using flowcytometry. TLR2 and tumor
necrosis factor αmRNA expression were also evaluated by real-time PCR.
Results: TLR2 extracellular expression on the macrophages from induced sputum in long-term ICS treatment group
was lower than the ICS naïve group (13.69% ± 1.17% vs 20.12% ± 4.37%, p = 0.019). TLR2 intracellular expression in
the macrophages, the TLR2 and TNFαmRNA in the induced sputum also showed a trend towards decreased
endpoint in ICS long-term treatment group compare to ICS naïve group but did not reach significance. TLR2
extracellular and TLR2 intracellular expression were strongly related (r = 0.645, p = P = 0.017) as well as TNFαmRNA
and TLR2 mRNA expression (r = 0.894, p = 0.0001).
Conclusion: Long-term use of ICS may have negative influence on TLR2 expression in the airway of severe COPD
patient.
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Inhaled corticosteroids (ICS) are recommended by
current guidelines for use in the treatment of chronic
obstructive pulmonary disease (COPD) for those with
severe disease, defined as a forced expiratory volume in
first second (FEV1) <50% predicted and repeated exacer-
bations. Recent large prospective trials have reported an
increased incidence of pneumonia in COPD patients
using ICS on daily basis. This has raised concern about
long term safety of ICS therapy. The link between ICS
therapy and pneumonia remains controversial [1].* Correspondence: tina_tangwei@163.com
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Toll like receptor 2 (TLR2) is a critical component in
the host innate immune response to infections. TLR2
signaling has been proposed to be involved in the
pathogen recognition process during the infection of
Streptococuus, mycoplasma, chlamydia, virus, which
are the common pathogens that cause exacerbations
and pneumonia in COPD [2-5]. Because of this, we hy-
pothesized that long-term use of inhaled corticosteroid
may down-regulate TLR2 expression therefore reducing
microbial recognition. In this study, we investigated
severe COPD patients who receiving long term ICS
treatment and compared the expression of TLR2 in the
macrophages from induced sputum.Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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Subjects
The ethnic review board of Ruijin hospital affiliated to
Shanghai Jiaotong University school of medicine ap-
proved the study, and informed consent was obtained
from all subjects. According to the Global Initiative for
Chronic Obstructive Lung Disease (GOLD) and the
Chinese guideline on Chronic Obstructive lung disease,
51 severe stable COPD patients who were in stage III
and IV with FEV1 less than 50% predicted value were in-
vestigated in this study. Patients who had an exacerba-
tion in the previous 6 weeks or who were hospitalized in
the previous 3 months were excluded from the study.
Patients on oral steroids or who concomitantly suffered
from bronchiactasis, chronic fungus infections and
asthma were also excluded.
Induced sputum processing
Spirometry was recorded 15 min after inhalation of
200ug salbutamol via a metered-dose inhaler. Subjects
inhaled 3% saline at room temperature, nebulized via an
ultrasonic nebulizer (ShuangYuW Ultrasonic nebulizer,
China) at maximum output for 20 minutes. Subjects
were encouraged to cough deeply. Sputum was coughed
into polypropylene pots. Saliva was discarded. If bother-
some symptoms occur, the nebulization should be
stopped and the subject treated with salbutamol. After
the sputum induction, spirometry was repeated. If the
FEV1 falls by more than 20%, the subject was required
to wait until it had returned to baseline value.
Sputum processing
The sputum samples were kept at 4°C for not more than
2 h prior to further processing. The portion of the
sample for cell counting was diluted with 8 ml 1%
dithiothreitol (DTT) (shanghai ZiYi reagent, China) and
gently vortexed. The resultant cell suspension was then
filtered through 400 μm sieves. After centrifuge with
1500 rpm for 10 minutes, cell pellet were washed twice
with PBS containing 2% FCS, then resuspended in PBS.
Total cell counting was carried out on a hemacytometer
and cell viability was calculated by using the trypan
blue. Cells were adjusted to a concentration of 1 × 105/
ml and use 0.5 ml cell suspension for flow cytometry
staining. The remaining cells were centrifuged and
resuspended to be used in later RT-PCR testing.
Flowcytometry analysis
For extracellular staining, 10 ul mouse anti-human CD14
FITC monoclonal antibody and 10 ul of mouse anti-
human TLR2 PE monoclonal antibody or relative IgG
antibody were added, incubated for 1 hour. For intracellu-
lar staining, 10 ul mouse anti-human CD14 FITC mono-
clonal antibody was added to the cell suspension andincubated for 1 hour in room temperature first. The
sample was then fixed with 4% paraformaldehyde for
20 minutes. The cells were resuspended with 200 ul
0.1% saponin for 10 minutes. Mouse anti-human TLR2
PE monoclonal antibody 10 ul or relative IgG antibody
were added to the sample and incubated for 1 hour.
(Antibodies all from eBioscience, USA) Cells were then re-
suspend in PBS and acquired on a flow-cytometry. The ex-
pression of extra and intracellular TLR2 from macrophages
was identified by both positive staining for TLR2 and CD14
staining. (BECTON-DICKINSCN FACS Calibur, BD Bio-
sciences) Cellquest software was used for the analysis
(eBioscience, USA).
RT-PCR
We examined the expression of TLR2mRNA and TNFα-
mRNA expression in the induced sputum from severe
COPD subjects of long term ICS therapy compared to
subjects on no long term therapy. Among all the sputum
samples, 12 in ICS naïve group and 10 in ICS group have
the remaining cells for RT-PCR testing after flowcytometry
testing. Target gene expression was analysed using quanti-
tative real-time PCR. Briefly, RNA was extracted and
reverse-transcribed to cDNA. The oligonucletoide primers
for TLR2 were: upper: 50 GGG TCT TGG GGG TCA
TCA T 30; lower: 50 CAG AGC CTG GAG GTT CAC A
30; Primes for TNFαwas: upper:50 AGA GGG AGA GAA
GCA ACT ACA G 30; lower: 50 CCG TGG GTC AGT
ATG TGA G 30. Reactions were characterized by com-
paring the threshold cycle (CT) values. Taqman qPCR
probes for TLR2 and TNFαmRNA were purchased in
kit form, combined with the reference gene eukaryotic
18S ribosomal RNA in dupliate real-time PCRs chains
(ABI prism7900 Real Time PCR Machine, Applied
Biosystems, USA) and results were calculated using 2-
ΔCt relative to the housekeeping gene (18S) and an in-
ternal calibrator. (2-ΔCt = the difference in threshold
cycles for the test gene and beta actin).
Statistical analysis
Expression levels are expressed as means +/− SD. Com-
parisons between the two groups were performed by
SPSS 11.0 version software of independent-samples T
test. Use Pearson correlation test for determine the
association between mRNA level and TLR2 expression.
A p value < 0.05 was considered significant.
Results
General characteristics of subjects
All of our subjects were male and smokers or ex-smokers.
We divided these patients into two groups according to
the treatment history: Long term ICS treatment group
(with fluticasone propionate (FP) use ≥ 500 ug/day for
more than 1 year) and ICS naïve group (without routine
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duration was 1.65 ± 0.75y (1–3.5 years). Most patients
received FP 250 ug twice daily inhaled. (20 in 21 subjects,
the other subject received 500 ug FP twice daily inhaled
treatment). The demographic data in both groups are
shown in Table 1. Except the ICS use duration, the demo-
graphic characteristics data between these two groups
showed no statistical difference.
Impairment of TLR2 expression on macrophage in COPD
patient who treated with ICS
The expression of TLR2 was identified as both extra-
cellular (surface expression) and intracellular in the
induced sputum macrophages (CD14+ TLR2+ cell)
(Figure 1). In the ICS naïve group, the TLR2 intracellular
expression was 20.12% ± 4.37% and extracellular expres-
sion was 12.81% ± 4.89%. In the ICS treatment group
(patients received ICS treatment more than one year
and ≥500 ug/day fluticasone propionate), the TLR2
intracellular expression was 13.69% ± 1.17% and extra-
cellular expression was 5.35% ± 1.67%. The extracellular
expression of TLR2 on induced sputum macrophages in
ICS treatment group was significantly lower than ICS
naïve group (p = 0.019) (Figure 2).
TLR2 and TNFαmRNA expression in induced sputum from
COPD subjects
Constitutive mRNA expression was measured for TLR2
and TNFα (tumor necrosis factor α) from induced spu-
tum in severe COPD patients. Values have been normal-
ized to the expression of the house keeping gene. The
TLR2 mRNA and TNFαmRNA expression slightly de-
creased in ICS treatment group compare to ICS naïve
group but this did not reached statistical significance.Table 1 Demographic characteristics of study participants
ICS group
Age (years) 66 (79–54
Gender (female/male) 0/21
Duration of COPD (year) 5 (1–25)
Smokers/ex-smokers 9/21
Smoking (pack/year) 56 (82–20
BMI (kg/m2) 27 (35–20
Post BD FEV1 (%predicted) 43% (15–5
FEV1/FVC 32% (12-4
MRC† Dyspnoea Score 2 (2–3)
Hospitalization in the previous year (number) 0.5 (0–1)
Pneumonia in the previous 3 years (number) 0.6 (0–1)
Non of ER visit because of exacerbation of COPD in
the previous year (number)
1.1 (1–3)
†: MRC =Modified Medical Council.
Data represents: mean (range).(Table 2) Pearson correlation test was used to determine
the association between mRNA level and TLR2 expres-
sion as well as TLR2 mRNA and TNFαmRNA expres-
sion. A statistically significant correlation between
intracellular and extracellular expression of TLR2 in
both groups was observed (r = 0.645, p = 0.017). A stron-
ger correlation between TLR2 mRNA and TNFαmRNA
expression was also observed (r = 0.894, p = 0.000).
Discussion
Recurrent airway infections are the leading cause of
COPD exacerbation, which are also strongly related to
the prognosis of COPD. COPD patients are susceptible
to bacterial and virus infections probably due to local
airway immunity impairment [6]. Innate immunity is the
first line of defense against infection and toll-like recep-
tor mediated recognition of pathogens is essential. Im-
pairment of the TLRs leads to an increase in pathogen
susceptibility in COPD patients. For example, TLR2 is
involved in the host immunity during pulmonary infec-
tion with pathogen like Chlamydia pneumoniae and
Mycoplasma pneumoniae [7,8]. Droemann et al. found
decreased TLR2 expression on alveolar macrophages
from COPD patients and smokers [9]. It was also
reported the expression of TLR2 on CD14 +monocytes
in peripheral blood from stable COPD patients and
healthy smokers were significantly decreased compare to
healthy nonsmokers. In the same study the author
showed a down-regulation of TLR2 was associated with
reduced lung function parameters [10].
Inhaled corticosteroid is currently being suggested as
the standard therapy in COPD guideline for severe or
patients with recurrent exacerbations [11]. However, some
epidemiological data showed an increased incidence of(n = 21) ICS naïve group (n = 29) P value
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) 26 (38–19) 0.23
0) 48% (17–49) 0.47





Figure 1 Intracellular and surface expression of TLR2 on macrophages in induced sputum. Flowcytometry results from typical subjects in
the two groups. Right upper quardrant presents the events of the percentage of both positive in TLR2 and CD14 staining. From upper to bottom:
extracelluar expression of TLR2, intracellular expression.
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combination therapy which included inhaled corticoste-
roids in COPD patients [12-14]. Gram positive bacteria
like streptococcus pneumoniae, atypical pathogen like
mycoplasma and chlamydia infections are major patho-
gens that cause community-acquired pneumonia and ex-
acerbation of COPD [2,4,8,15]. Therefore, long-term use
of ICS in COPD patients could cause an inhibition of the
innate immunity to infection should be examined. In oneFigure 2 Comparison of TLR2 surface (extracellular) and
intracellular expression in the induced sputum macrophages
between ICS naïve group and ICS long term treatment groups.
Bar presents the mean value. *p < 0.05 comparison between the
two groups.vitro study, Von Scheel et al. found that in bronchial
epithelial cell culture, inhaled steroids budesonide (1.5-6 -
hours) did not influence TLR2 expression. But when co-
stimulated with LPS, TNF, or dust together, budesonide
increased TLR2 expression synergistically [16]. This result
may reflected ICS role on the epithelial cell innate im-
mune function during exacerbation status. But the long-
term ICS use influence on airway local innate immunity
had not been issued until now. In another study, the ex-
pression of TLR2 and CD14 on alveolar macrophages
(AM) from COPD patients, smokers and non-smokers
was reduced as compared to autologous monocytes. Com-
paring AM the author detected a reduced expression of
TLR2 in COPD patients and smokers. In addition TLR2
mRNA and protein expression was increased after LPS
stimulation on non-smokers AM in contrast to smokers
and COPD patients [17]. In this retrospective study, we di-
vided severe COPD patients into two groups according to
whether they received inhaled corticosteroids for moreTable 2 TLR2 mRNA and TNFαmRNA expression in
induced sputum from COPD patients
mRNA expression ICS naïve group ICS group p value
TNFα 8.18 ± 1.49 6.92 ± 2.23 0.31
TLR2 5.13 ± 1.41 3.64 ± 1.61 0.37
Data represents: Mean ± SD.
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mostly treated in primary hospitals where ICS were not
popular used in COPD patients. In order to minimize the
bias, we selected subjects with the same age and same
smoking history as well as the same gender in both
groups. We observed that the TLR2 extracellular expres-
sion in the long-term ICS treatment group was signifi-
cantly lower than the ICS naïve group. The TLR2
intracellular expression, TLR2mRNA and TNFαmRNA
expression was also decreased in ICS long-term treatment
group compare to ICS naïve group but this didn’t reached
statistical significance. In Von’s study, it showed expres-
sion of TLR2 was lower on sputum neutrophils and sol-
uble TLR2 (sTLR2) was higher in the supernatant in the
COPD group. This may be one explanation of TLR2 ex-
pression difference between the surface and intracellular
expression on the immune cells [6]. And we couldn’t ex-
clude the contamination of neutrophil when use CD14 as
the surface marker of macrophages. Our results suggest
long-term use of ICS might have negative influence on the
TLR2 expression in the airway macrophages of COPD pa-
tients. There was a strong relationship between the TLR2
extracellular and intracellular expression. But the mechan-
ism caused the difference between TLR2 expression still
needs to be elucidated.
The decreased TLR2 expression may be related to the
inhibition of the transcription factor nuclear factor NF-
κB activation pathway. The inhibition of NF-κB activa-
tion pathway is one of the main anti-inflammatory
mechanisms of inhaled corticosteroid. At the same time,
NF-κB activation is also the main pathway that innate
immunity used against pathogenic microorganisms [18].
Both vitro and vivo studies showed that pathogen like
streptococcus pneumonia and mycoplasma induce their
pathogenic invasion through TLR2 activation, which is
dependent on NF-κB pathway [14,15,18-21]. Therefore,
the inhaled corticosteroid using the same pathway for
anti-inflammatory effects may weaken the innate im-
munity to pathogen. In our study, a strong relationship
between TNFα and TLR2 mRNA expression was ob-
served. It was also reported that the expression of
proinflammatory cytokine TNFα mRNA was strongly re-
lated to the NF-κB activation in asthma and COPD pa-
tients [18]. These results suggest the expression of both
TNFα and TLR2 may be impaired by the same mechan-
ism. Whether long-term use of inhaled corticosteroids
which inhibits TLR2 expression, is related to NF-κB acti-
vation pathway still needs further investigation.
Conclusion
We conducted this study in severe COPD male patients
with heavy smoke histories in order to identify the effect
of long term use of inhaled corticosteroid effect on
TLR2 expression on macrophages from induced sputum.This study showed long-term use of ICS has a negative
influence on TLR2 expression of COPD patients, which
might be one explanation for increased pulmonary infec-
tion susceptibility.
Summary at a glance
We compared TLR2 expression with flowcytometry and
RT-PCR in severe male smoking COPD patients with or
without long-time ICS treatment. The result showed
TLR2 extracellular expression on the macrophages from
induced sputum in long-term ICS treatment group was
lower than the ICS naïve group.
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